The company reported a net loss of $9.9M on $6.1M of revenue, reflecting a deeply negative -106.78% net margin that highlights significant operational overhead.
| Revenue | 14.29M | 11.32M | 10.05M | 9.7M | 10.66M |
| Revenue Growth % | - | 12.63% | 3.6% | -8.98% | - |
| Medical Costs & Claims | 14.63M | 2.53M | 2.25M | 2.34M | 2.18M |
| Medical Cost Ratio % | 102.37% | 22.32% | 22.37% | 24.09% | 20.44% |
| Gross Profit | -339K | 8.79M | 7.8M | 7.36M | 8.48M |
| Gross Margin % | -2.37% | 77.68% | 77.63% | 75.91% | 79.56% |
| Gross Profit Growth % | - | 12.7% | 5.95% | -13.15% | - |
| Operating Expenses | 4.19M | 10.98M | 5.61M | 5.36M | 6.01M |
| OpEx / Revenue % | 29.29% | 96.97% | 55.79% | 55.27% | 56.34% |
| Depreciation & Amortization | 2.85M | 1.18M | 528.73K | 557.13K | 575.92K |
| Combined Ratio % | 131.66% | 119.28% | 78.16% | 79.36% | 76.79% |
| Operating Income | -4.53M | -2.18M | 2.2M | 2M | 2.47M |
| Operating Margin % | -31.66% | -19.28% | 21.84% | 20.64% | 23.21% |
| Operating Income Growth % | - | -199.45% | 9.6% | -19.05% | - |
| EBITDA | -1.68M | -1M | 2.72M | 2.56M | 3.05M |
| EBITDA Margin % | -11.73% | -8.85% | 27.1% | 26.39% | 28.62% |
| Interest Expense | 317.49K | 203.95K | 176.24K | 238.6K | 320.87K |
| Non-Operating Income | 0 | 10.12M | -385.69K | -367.25K | -233.12K |
| Pretax Income | -10.01M | -12.51M | 2.4M | 2.13M | 2.39M |
| Pretax Margin % | -70.01% | -110.47% | 23.92% | 21.97% | 22.39% |
| Income Tax | -227.11K | -417.39K | 331.76K | 348.28K | 408.48K |
| Effective Tax Rate % | 2.27% | 3.34% | 13.8% | 16.34% | 17.12% |
| Net Income | -9.67M | -12.09M | 2.07M | 1.78M | 1.98M |
| Net Margin % | -67.66% | -106.78% | 20.62% | 18.38% | 18.56% |
| Net Income Growth % | - | -683.15% | 16.23% | -9.84% | - |
| EPS (Diluted) | - | -5.16 | 1.14 | 0.96 | 1.07 |
| EPS Growth % | - | -554.55% | 17.66% | -10.17% | - |
| EPS (Basic) | - | -5.16 | 1.14 | 0.96 | 1.07 |
| Diluted Shares Outstanding | 1.57M | 1.57M | 1.35M | 1.35M | 1.35M |
Unsustainable Operating Overhead
As reported in the 2024Q4 financial statements, BMGL recorded a combined ratio of 126.7%, driven by an 89.4% loss ratio, which indicates that the company is currently failing to achieve underwriting profitability and is relying on external capital to sustain its core medical service operations.
The combined ratio exceeding 100% suggests that the cost of claims and administrative expenses significantly outpaces the premiums earned. This level of underwriting inefficiency warrants further investigation into whether the company's pricing models are adequate or if the current specialist-heavy cost structure is inherently unscalable.
Based on the latest quarterly figures, the company's operating margin of -19.28% against a 77.68% gross margin highlights a massive disconnect between service-level profitability and corporate-level sustainability, suggesting that administrative and fixed costs are currently overwhelming the firm's ability to generate meaningful operating leverage.
The stark divergence between gross and operating margins implies that BMGL is struggling to absorb its corporate overhead as it scales. Investors should monitor whether management can rationalize these fixed costs or if the current business model requires significantly higher volume to reach a break-even point.
According to the 2024Q4 data, the net loss of $9.9M on $6.1M of quarterly revenue suggests a net margin of -106.78%, which indicates that the company's current cash burn rate is likely unsustainable without immediate capital injections or a drastic shift in the underlying cost structure.
The significant gap between revenue and net income suggests that non-operating expenses or heavy startup investments are severely eroding shareholder value. This performance appears to indicate that the company is in a high-risk execution phase where the cost of growth is currently exceeding the value created by its integrated medical platform.
Quick answers to the most common questions about buying BMGL stock.
For fiscal year 2024, Basel Medical Group Ltd Ordinary Shares (BMGL) reported total revenue of $11.3M. This represents a 6.2% increase compared to $10.7M in 2021.
Basel Medical Group Ltd Ordinary Shares (BMGL) reported a net loss of $12.1M for the fiscal year ending 2024.
Basel Medical Group Ltd Ordinary Shares (BMGL) reported an operating income of $-2.2M, resulting in an operating profit margin of -19.3%. This margin reflects the operational efficiency of the business before interest and taxes.
Basel Medical Group Ltd Ordinary Shares (BMGL) generated $8.8M in gross profit for the year, representing a gross profit margin of 77.7%. This demonstrates the company's core pricing power and production efficiency.